PubMed Health⌕ Search

Biomedical subjects

I Eberhard

Publications and source records attributed to I Eberhard.

2 recordsLinked to original sources

Signal transduction pathways induced by heregulin in MDA-MB-453 breast cancer cells.

Heregulins (HRGs) induce tyrosine phosphorylation of several members of the erb-B family of receptors. Although originally isolated as the ligands for p185c-erb-2, recent evidence suggests that other receptors of the erbB family, including p180erbB-3 and p180erbB-4, are their true cognate receptors. Stimulation of MDA MB-453 cells with HRG beta 2 resulted in the tyrosine phosphorylation of p185c-erbB-2 and p180erbB-4 in a time- and dose-dependent fashion. This event was accompanied by the formation of multimeric complexes between the activated receptors and SH2-containing proteins. Ligand caused p120-rasGTPase activating protein (GAP), SHC and the p85 subunit of phosphatidylinositol-3'-kinase (PI3K) to be associated with both p185c-erbB-2 and p180erbB-4. In addition, tyrosine phosphorylation of p85-PI3K and SHC, but not of GAP or of its associated p62 and p190 proteins, was also detected. HRG also induced the association of GRB2 with tyrosine phosphorylated p185c-erbB-2, p180erbB-4 and SHC. Activation of mitogen-activated protein kinase (MAPK) ( > 30-fold over untreated controls) was observed upon receptor(s) activation, as it was the induction of the immediate early gene c-fos ( > 200-fold). These observations suggest that p21ras activation plays a role in the HRG pathway. Furthermore, comparative analysis of the binding of p85-PI3K to 185c-erbB-2 and p180erbB-4, revealed a preferential association with activated p180erbB-4. These findings might suggest a model of HRG action in which the relative expression of the various erb-B family members and the partitioning of signal transduction molecules between each type of receptor might determine the nature of the signal elicited by the ligand and the biological response attained.

1-Phosphatidylinositol 4-Kinase↗

[First experiences with temporary vena cava filters].

AIM: For prophylactic measures we used 3 different temporarily insertable vena cava filters. MATERIAL AND METHODS: In 49 patients we inserted 12 Cook-filters (6 transjugular, 6 transfemoral), 11 Angio-cor-filters (1 transjugular, 10 transbrachial), 26 Antheor-filters (1 transjugular, 1 transfemoral, 24 transbrachial). 35 patients underwent a lysis therapy, 11 a major operation of the pelvis, and 3 patients a Caesarean section. RESULTS: No patient suffered from a clinically significant pulmonary embolism after filter insertion, but complications occurred caused by the basic therapy (1 lethal abdominal aortic aneurysm operation, 1 cerebral bleeding, 2 retroperitoneal haematomas, 2 streptokinase fever reactions, 1 compartment syndrome, 1 macro-haematuria) or by therapy joined with the filters insertion (2 groin haematomas, 2 haematomas of the bend of the elbow, 2 subclavian vein thrombosis, 1 catheter dislocation, 1 infection, 1 air embolism, 1 break of a leg of the filter basket). CONCLUSION: Temporary vena cava filters are highly efficient in preventing pulmonary embolism, but the side-effects show that they should only be inserted in patients with known deep vein thrombosis and a high risk treatment of the underlying disease.

Evaluation Studies as Topic↗